Abstract 366P
Background
Microbiome has been proposed as a promising prognostic biomarker in various types of cancer. Although recent microbiome studies have linked the bacterial microbiome in the oral cavity and nasopharynx to the prognosis of nasopharyngeal carcinoma (NPC), the clinical significance of oral mycobiome, another key player of the oral microbiome, in NPC survival remain unknown.
Methods
We enrolled 476 untreated incident NPC patients from Wuzhou, southern China during March 2010 and December 2013, with follow-up through December 2018. We collected saliva samples at the time of diagnosis and characterized the oral mycobiome using fungal internal transcribed spacer (ITS)-2 sequencing. We analyzed the relationship between oral mycobiome and the overall survival using Cox regression adjusting for multiple confounders.
Results
Overall, the average follow-up of the NPC patients [mean (SD) age, 48.5 (10.7) years; 72% male) was 5.26 years. Patients with lower oral fungal alpha diversity (measured by observed features) had an inferior 5-year overall survival rate (lower group vs. higher group = 54.9% vs. 69.6%, P for log-rank test = 0.007). We found that lower alpha diversity was associated with an increased mortality [lower vs. higher: observed features (fully adjusted hazard ratio [HR] = 1.56, 95% confidence interval [CI] = 1.08-2.25); Simpson diversity (1.50, 1.04-2.15); Shannon diversity (1.79, 1.25-2.56)]. The associations were attenuated when further adjusted for cancer stage at diagnosis, and the significant associations were found only among localized-tumor-stage patients.
Conclusions
Oral mycobiome is a potential prognostic biomarker for patients with NPC and might provide potential guidance for treatment decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The original field work was supported by a grant from the National Cancer Institute at the US National Institutes of Health (grant number: R01 CA115873). This work was supported by the Swedish Research Council (grant numbers: 2015-02625, 2015-06268, 2017-05814, 2019-01429), and the High-level Talents Research Start-up Project of Fujian Medical University (grant numbers: XRCZX2017035 and XRCZX2020034), the National Natural Science Foundation of China (grant number: U22A20322). Yufeng Chen was also partly supported by a scholarship from China Scholarship Council (grant number: 201600160071).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract